EyePoint at Goldman Sachs Healthcare Conference

 On Tuesday, 10 June 2025, EyePoint Pharmaceuticals (NASDAQ:EYPT) presented at the Goldman Sachs 46th Annual Global Healthcare Conference. The company spotlighted its strategic advancements in sustained-release treatments for retinal diseases, revealing promising trial data and operational strides. While EyePoint’s cash reserves provide a robust runway, challenges remain in achieving full trial enrollment and navigating regulatory approvals.

Key Takeaways

• EyePoint is advancing Phase III trials for Duravu in wet AMD, with the Lugano trial fully enrolled.
• Positive Phase II results for Duravu in diabetic macular edema show improved efficacy and safety.
• EyePoint’s cash position of $318 million supports operations into 2027.
• A new manufacturing facility in Northbridge, MA, is now operational, enhancing production capacity.
• The company plans to submit a New Drug Application (NDA) by 2026.

Financial Results

• Cash Position: EyePoint reported $318 million in cash at the end of Q1 2025.
• Cash Runway: This financial cushion extends operational capabilities into 2027, beyond the anticipated Phase III trial data readout.

Operational Updates

• Lugano Trial Enrollment: The Lugano Phase III trial in wet AMD is fully enrolled with over 400 patients.
• LUCIA Trial Enrollment: The LUCIA trial is 60% enrolled and is expected to reach full enrollment in Q3 2025.
• Manufacturing Facility: EyePoint’s new facility in Northbridge, MA, meets U.S. FDA and EMA standards, with a capacity of over one million inserts annually.

Future Outlook

• NDA Submission: EyePoint aims to submit an NDA by the end of the two-year trial period.
• Lugano and LUCIA Data: Top-line data for the Lugano trial is expected in mid-2026, followed by LUCIA data several months later.
• DME Pivotal Trial: Plans to initiate pivotal trials for DME in 2026.

Transcript:

https://www.investing.com/news/transcripts/eyepoint-at-goldman-sachs-healthcare-conference-sustainedrelease-vision-93CH-4089882

Revvity at Goldman Sachs Conference

 On Tuesday, 10 June 2025, Revvity Inc (NYSE:RVTY) participated in the Goldman Sachs 46th Annual Global Healthcare Conference, outlining its strategic direction amidst a challenging market environment. CEO Prahlad Singh emphasized the company’s transformation and resilience, highlighting a shift towards diagnostics and software. While Revvity faces hurdles in the life sciences segment, it remains optimistic about its growth prospects and strategic initiatives.

Key Takeaways

• Revvity’s diagnostics and software now account for 60% of revenue, aligning with its long-range plan.
• The company maintains an organic growth guidance of 3% to 5% for the year.
• Share buybacks are prioritized, with $450 million executed over the last three quarters.
• Revvity is expanding its specialty diagnostics, particularly in neurological issues.
• The company is mitigating a $135 million tariff impact with global manufacturing capabilities.

Financial Results

• Revenue Composition: 60% from diagnostics and software.
• Organic Growth: Projected at 3% to 5% for the year.
• Gross Margin: Improved to 28% from a previous range of 18% to 20%.
• Share Buybacks: $150 million in Q4, $150 million in Q1, and $150 million+ in Q2.

Operational Updates

• Innovation: Launching nearly 2,000 new consumables annually.
• Software Business: Represents 8% to 9% of revenue, growing in the mid to high teens.
• Immunodiagnostics: U.S. exposure at 15% to 20%, with plans to expand.
• China Strategy: Focus on IP-protected assays and reproductive health menu expansion.
• Strategic Partnership: Collaboration with Genomics England.

Future Outlook

• Growth Opportunity: Immunodiagnostics in the U.S. seen as a significant growth driver.
• Software Expansion: Continued focus on bolstering the software business.
• Capital Deployment: Emphasis on cell and gene therapy and diagnostics enhancements.
• Specialty Diagnostics: Focus on neurological and rare disease testing.
• 
  
• Q&A Highlights

• Organic Growth: Variance observed in life sciences and diagnostics segments.
• Instrument Margins: Higher margins with consumables compared to instruments.
• CapEx Pressure: Capital expenditure remains pressured.
• Regional Manufacturing: Continued focus despite tariff challenges.
• Specialty Focus: Emphasis on providing differentiated specialty diagnostics.

For more detailed insights, readers are encouraged to review the full conference call transcript.

Full transcript - Goldman Sachs 46th Annual Global Healthcare Conference:

https://www.investing.com/news/transcripts/revvity-at-goldman-sachs-conference-diagnostics-and-software-focus-93CH-4088925

Bio-Techne at Goldman Sachs Conference

 On Tuesday, 10 June 2025, Bio-Techne (NASDAQ:TECH) participated in the Goldman Sachs 46th Annual Global Healthcare Conference. The company presented a robust strategic overview, reporting solid Q3 results with notable growth in the protein sciences segment. However, challenges in the U.S. academic market and uncertainties in large pharma were highlighted. Despite these hurdles, Bio-Techne remains optimistic about its long-term growth, backed by strategic initiatives and a significant share repurchase plan.

Key Takeaways

• Bio-Techne achieved 6% organic growth in Q3, with strong performance in protein sciences.
• The company announced a $500 million share repurchase plan, signaling confidence in its valuation.
• Challenges include a choppy U.S. academic market and negative growth in China.
• Bio-Techne focuses on strategic areas like cell and gene therapy and spatial biology.
• Tariff impacts are expected to affect Q4 margins, but mitigation strategies are in place.

Financial Results

• Organic Growth: 6% overall growth in Q3, driven by a 7% increase in the protein sciences segment.
• Large Pharma: Double-digit growth in this segment, which accounts for 30% of revenue.
• China Market: Experienced negative mid-single-digit growth, but long-term potential remains.
• U.S. Academic Market: Represents 12% of revenue, with a stable core reagents business despite market fluctuations.
• Margin Performance: Q3 margins expanded by nearly 200 basis points; however, Q4 is expected to see a decrease due to tariff impacts.

Operational Updates

• Tariff Mitigation: Efforts include shifting manufacturing outside China to reduce exposure.
• Instrument Performance: Upper single-digit growth in instrumentation, with strong contributions from the Protein Simple franchise.
• Cell and Gene Therapy: Revenue exhibits variability due to clinical trial purchase timings.
• Spatial Biology: This business area is nearing $120 million in revenue, with an EBITDA approaching 30%.
• Wilson Wolf: Growth in the mid-twenties on a TTM basis, supported by involvement in five approved cell therapies.
• 
  
• Future Outlook

• Q4 Expectations: Anticipated to mirror Q3 performance, with potential slowdowns in large pharma.
• M&A Strategy: Continues to be a key focus, with potential for increased activity as valuations improve.
• Capital Allocation: The share repurchase plan reflects a tactical move, not a shift in long-term priorities.
• China’s Market: Expected to remain the fastest-growing region for life science tools over the next decade.

Q&A Highlights

• Jim Hipple, CFO: Emphasized a solid quarter despite challenging market conditions.
• Academic Revenue: Highlighted the difficulty in directly correlating revenue to NIH funding.
• Recovery Outlook: Expressed optimism about a quick recovery when market conditions improve.
• Stock Valuation: Reiterated confidence in the company’s undervalued stock, justifying the share repurchase plan.

Readers are encouraged to refer to the full transcript for a detailed account of the conference call.

Full transcript - Goldman Sachs 46th Annual Global Healthcare Conference:

https://www.investing.com/news/transcripts/biotechne-at-goldman-sachs-conference-strategic-growth-amid-challenges-93CH-4089489